Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COACH trial of once-weekly navepegritide and lonapegsomatropin in children with achondroplasia
2023-508341-40-00Phase 2Authorised
- Sponsor
- Ascendis Pharma
- Start
- Jul 2024
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of navepegritide and lonapegsomatropin in achondroplasia (ACH) (2 cohorts), sponsored by Ascendis Pharma. Primary endpoints: Annualized growth velocity at Week 52 and Treatment-emergent adverse events. Planned start Jul 2024; status: authorised.
02
Drugs
navepegritidelonapegsomatropin
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2023-508341-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508341-40-00.